ArticleOncotarget2016
Dextran-Catechin: An anticancer chemically-modified natural compound targeting copper that attenuates neuroblastoma growth.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 47 citations in OpenAlex.
- An Update on Antitumor Efficacy of Catechins: From Molecular Mechanisms to Clinical Applications.Food science & nutrition · 2025Review
- How Do Cyclodextrins and Dextrans Affect the Gut Microbiome? Review of Prebiotic Activity.Molecules (Basel, Switzerland) · 2024Review
- Antioxidant and Anti-Aging Properties of Polyphenol-Polysaccharide Complex Extract fromFoods (Basel, Switzerland) · 2023Article
- New Methacrylated Biopolymer-Based Hydrogels as Localized Drug Delivery Systems in Skin Cancer Therapy.Gels (Basel, Switzerland) · 2023Article
- Comparative Study on the Structural Properties and Bioactivities of Three Different Molecular Weights ofMolecules (Basel, Switzerland) · 2023Article
- Hyaluronic Acid within Self-Assembling Nanoparticles: Endless Possibilities for Targeted Cancer Therapy.Nanomaterials (Basel, Switzerland) · 2022Review
- Structure similarity and molecular networking analysis for the discovery of polyphenol biotransformation products of gut microbes.Analytica chimica acta · 2022Article
- Dextran-Curcumin Nanosystems Inhibit Cell Growth and Migration Regulating the Epithelial to Mesenchymal Transition in Prostate Cancer Cells.International journal of molecular sciences · 2021Article
- The Multiple Potential Biomarkers for Predicting Immunotherapy Response-Finding the Needle in the Haystack.Cancers · 2021Review
- Phytochemicals in Chemoprevention: A Cost-Effective Complementary Approach.Journal of Cancer · 2021Review
- Role of Phytochemicals in Cancer Prevention.International journal of molecular sciences · 2019Review
- Injectable Hydrogels for Cancer Therapy over the Last Decade.Pharmaceutics · 2019Review
- Antioxidant and pro-oxidant mechanisms of (+) catechin in microsomal CYP2E1-dependent oxidative stress.Toxicology in vitro : an international journal published in association with BIBRA · 2019Article
- Synthesis of Dextran-Phenoxodiol and Evaluation of Its Physical Stability and Biological Activity.Frontiers in bioengineering and biotechnology · 2019Article
- Graphene Oxide Functional Nanohybrids with Magnetic Nanoparticles for Improved Vectorization of Doxorubicin to Neuroblastoma Cells.Pharmaceutics · 2018Article
- Anti-Cancerous Potential of Polyphenol-Loaded Polymeric Nanotherapeutics.Molecules (Basel, Switzerland) · 2018Review
- Article
- Polyphenols delivery by polymeric materials: challenges in cancer treatment.Drug delivery · 2017Review
- Dextran-Catechin inhibits angiogenesis by disrupting copper homeostasis in endothelial cells.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroblastoma is frequently diagnosed at advanced stage disease and treatment includes high dose chemotherapy and surgery. Despite the use of aggressive therapy survival rates are poor and children that survive their disease experience long term side effects from their treatment, highlighting the need for effective and less toxic therapies. Catechin is a natural polyphenol with anti-cancer properties and limited side effects, however its mechanism of action is unknown. Here we report that Dextran-Catechin, a conjugated form of catechin that increases serum stability, is preferentially and markedly active against neuroblastoma cells having high levels of intracellular copper, without affecting non-malignant cells. Copper transporter 1 (CTR1) is the main transporter of copper in mammalian cells and it is upregulated in neuroblastoma. Functional studies showed that depletion of CTR1 expression reduced intracellular copper levels and led to a decrease in neuroblastoma cell sensitivity to Dextran-Catechin, implicating copper in the activity of this compound. Mechanistically, Dextran-Catechin was found to react with copper, inducing oxidative stress and decreasing glutathione levels, an intracellular antioxidant and regulator of copper homeostasis. In vivo, Dextran-Catechin significantly attenuated tumour growth in human xenograft and syngeneic models of neuroblastoma. Thus, Dextran-Catechin targets copper, inhibits tumour growth, and may be valuable in the treatment of aggressive neuroblastoma and other cancers dependent on copper for their growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.